Welcome to our dedicated page for METLIFE SEC filings (Ticker: MET), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on METLIFE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into METLIFE's regulatory disclosures and financial reporting.
METLIFE INC (MET) reported that executive vice president Bill Pappas had 4,030 shares of common stock withheld on August 31, 2026 at $95.17 per share to pay tax liabilities on shares issued for restricted stock units. After this withholding, he holds 79,716 shares directly, plus 10,220 shares indirectly through a 2024 GRAT and 18,750 shares indirectly through a 2025 GRAT.
METLIFE INC (MET) reported that EVP & Chief Financial Officer John D. McCallion had 6,057 shares of common stock withheld on August 31, 2026 to pay tax liabilities related to vested restricted stock units at a price of $95.17 per share. Following this withholding, he directly holds 269,137 shares of MET common stock; no Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) reported an insider transaction by EVP & Chief Risk Officer Marlene Debel on August 31, 2026. Debel had 4,030 shares of Common Stock withheld to pay tax liabilities on shares issued from restricted stock units, at a reference price of $95.17 per share. This was not an open-market sale but a tax-withholding disposition, and Debel held 150,350 shares of MetLife common stock directly after the transaction. No Rule 10b5-1 trading plan is reported for this filing.
METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, had 4,366 shares of common stock disposed of on August 31, 2026 to satisfy tax obligations on recently vested restricted stock units. The shares were withheld by the company for tax payment, and he directly holds 212,580 shares afterward.
METLIFE INC (MET) filed a notice under Rule 144 covering a proposed sale of 15,400 shares of common stock for the account of a Separate Account, with Barclays as broker and sales expected on or about 08/28/2026 on the NYSE. The filing states that 635,476,927 shares of MetLife common stock were outstanding. It also lists recent Rule 144 sales from various Separate Accounts and MetLife 401k plan trusts, including 128 shares for gross proceeds of $10,490.88 on 05/28/2026 and 332 shares for $28,412.56 on 06/18/2026.
METLIFE INC (MET) has a notice of proposed sale under Rule 144 for its common stock. An affiliate "Separate Account" plans to sell 104 shares of common stock, with an aggregate market value of $9,811.36, through Barclays on the NYSE, with an intended sale date of August 24, 2026. The filing states that there were 635,476,927 shares of common stock outstanding as of that notice. The 104 shares to be sold were acquired on December 17, 2019 by purchase from Bank of America and paid for in cash on December 19, 2019. The notice also lists several small common stock sales during the past three months by MetLife separate accounts and MetLife 401k plan vehicles.
METLIFE INC (MET) filed a notice under Rule 144 for a planned sale of its common stock for the account of MetLife Separate Account SPI, identified as an affiliate. The filing covers a proposed sale of 244 shares of MET common stock to be sold through Barclays on 08/20/2026, with an indicated value of $23,206.84.
The shares were originally acquired by purchase through Goldman Sachs on 05/29/2015. The notice also lists several small sales of MET common stock by related MetLife accounts and plans over the past three months, each involving modest share counts and dollar amounts.
MetLife, Inc. declared third quarter 2026 dividends on several series of preferred stock. The board approved a $0.31471411 quarterly dividend per share on the floating rate non-cumulative preferred stock, Series A, with a $25 liquidation preference. It also declared a $29.375 semi-annual dividend per share on the 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a $1,000 liquidation preference.
For the 5.625% non-cumulative preferred stock, Series E, MetLife declared a quarterly dividend of $351.5625 per share, or $0.3515625 per depositary share representing a 1/1,000th interest, and for the 4.75% non-cumulative preferred stock, Series F, a quarterly dividend of $296.875 per share, or $0.296875 per depositary share. These dividends are payable on September 15, 2026 to shareholders of record as of August 31, 2026.
MetLife, Inc., as an institutional investment manager, submitted a Form 13F report covering certain equity holdings over which its investment subsidiaries exercise investment discretion. MetLife states that it disclaims direct investment discretion and reports positions to the extent its ownership in these subsidiaries creates a reporting obligation. The report is filed as a 13F Combination Report and summarizes 6 portfolio entries with an aggregate reported value of $13,089,220.
MetLife, Inc.’s Board of Directors, acting as an entity, reports beneficial ownership of 102,098,469 shares of MetLife common stock, representing 16.1% of the outstanding class as of July 31, 2026. The shares are held in the MetLife Policyholder Trust for eligible policyholders and permitted transferees.
The Trustee holds legal title and votes the shares largely according to the Board’s recommendations, which causes the Board to be deemed a beneficial owner for voting purposes. Policyholder beneficiaries hold Trust Interests, direct the receipt of dividends and sale proceeds on their allocated shares, and may withdraw shares, including to participate in tender or exchange offers.